MetaVia Inc. Files 8-K
Ticker: MTVA · Form: 8-K · Filed: May 7, 2025 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Metavia INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | May 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, corporate-actions
Related Tickers: MTVA
TL;DR
MetaVia Inc. (MTVA) filed an 8-K on 5/7/25. Check financials & Reg FD.
AI Summary
MetaVia Inc. filed an 8-K on May 7, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides important updates on MetaVia Inc.'s regulatory disclosures and financial status, which are crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for disclosures and exhibits, not indicating any immediate material adverse events.
Key Numbers
- 001-37809 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- MetaVia Inc. (company) — Registrant
- NeuroBo Pharmaceuticals, Inc. (company) — Former company name
- Gemphire Therapeutics Inc. (company) — Former company name
- May 7, 2025 (date) — Date of report
- 0001638287 (company) — Central Index Key
- 472389984 (company) — IRS Employer Identification No.
FAQ
What specific Regulation FD disclosures are being made by MetaVia Inc. in this 8-K filing?
The filing indicates that Item 7.01 (Regulation FD Disclosure) is being utilized, but the specific details of the disclosure are not provided in the excerpt.
What financial statements or exhibits are included with this 8-K filing?
The filing states that Item 9.01 (Financial Statements and Exhibits) is applicable, indicating that financial statements and exhibits are part of the submission, though not detailed in the excerpt.
When was MetaVia Inc. formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc.?
The company was formerly known as NeuroBo Pharmaceuticals, Inc. after December 31, 2019, and prior to that, it was known as Gemphire Therapeutics Inc. until March 31, 2015.
What is MetaVia Inc.'s primary business sector?
MetaVia Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is MetaVia Inc. headquartered?
MetaVia Inc.'s principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, 02138.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 7, 2025 regarding MetaVia Inc. (MTVA).